Which has preferable valuation and earnings, TIL or FBRX?

Forte Biosciences is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is TIL or FBRX more profitable?

Instil Bio's return on equity of -39.76% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Forte Biosciences N/A -106.17% -85.50%

Which has better valuation & earnings, TIL or NERV?

Instil Bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Is TIL or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Minerva Neurosciences N/A N/A -32.63%

Is TIL or IKT more profitable?

Instil Bio's return on equity of -39.76% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Inhibikase Therapeutics N/A -41.31% -38.98%

Instil Bio (TIL) Competitors

$7.98 -0.04 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$8.00 +0.01 (+0.19%)

As of 04:10 PM Eastern

Compare

TIL vs. CHRS, FHTX, FBRX, NERV, and IKT

Should you buy Instil Bio stock or one of its competitors? MarketBeat compares Instil Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Instil Bio include Coherus Oncology (CHRS), Foghorn Therapeutics (FHTX), Forte Biosciences (FBRX), Minerva Neurosciences (NERV), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.

How does Instil Bio compare to Coherus Oncology?

Instil Bio (NASDAQ:TIL) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 727.07%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 537.25%. Given Instil Bio's higher probable upside, research analysts plainly believe Instil Bio is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.89 equaled Coherus Oncology'saverage media sentiment score.

Company	Overall Sentiment
Instil Bio	Very Positive
Coherus Oncology	Very Positive

Instil Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Coherus Oncology has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Coherus Oncology	$42.17M	4.97	$168.02M	$1.67	0.81

Coherus Oncology has a net margin of 397.30% compared to Instil Bio's net margin of 0.00%. Instil Bio's return on equity of -39.76% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Coherus Oncology	397.30%	-198.90%	-46.65%

Summary

Coherus Oncology beats Instil Bio on 8 of the 13 factors compared between the two stocks.

How does Instil Bio compare to Foghorn Therapeutics?

Instil Bio (NASDAQ:TIL) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Instil Bio has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Instil Bio currently has a consensus target price of $66.00, suggesting a potential upside of 727.07%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 196.85%. Given Instil Bio's higher possible upside, equities research analysts plainly believe Instil Bio is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Foghorn Therapeutics had 3 more articles in the media than Instil Bio. MarketBeat recorded 4 mentions for Foghorn Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.89 beat Foghorn Therapeutics' score of 0.30 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Foghorn Therapeutics	Neutral

Instil Bio has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Foghorn Therapeutics	$30.91M	7.31	-$74.28M	-$1.16	N/A

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Instil Bio has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, indicating that its stock price is 189% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Instil Bio on 9 of the 16 factors compared between the two stocks.

How does Instil Bio compare to Forte Biosciences?

Instil Bio (NASDAQ:TIL) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Instil Bio currently has a consensus target price of $66.00, indicating a potential upside of 727.07%. Forte Biosciences has a consensus target price of $67.00, indicating a potential upside of 298.34%. Given Instil Bio's higher possible upside, equities research analysts clearly believe Instil Bio is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Instil Bio's return on equity of -39.76% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Forte Biosciences	N/A	-106.17%	-85.50%

Forte Biosciences is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

In the previous week, Forte Biosciences had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Forte Biosciences and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.89 beat Forte Biosciences' score of 0.93 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Forte Biosciences	Positive

Instil Bio has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, suggesting that its share price is 187% more volatile than the broader market.

Summary

Forte Biosciences beats Instil Bio on 7 of the 13 factors compared between the two stocks.

How does Instil Bio compare to Minerva Neurosciences?

Instil Bio (NASDAQ:TIL) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.89 beat Minerva Neurosciences' score of 1.87 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Minerva Neurosciences	Very Positive

Instil Bio has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.18, suggesting that its share price is 118% less volatile than the broader market.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Instil Bio currently has a consensus price target of $66.00, suggesting a potential upside of 727.07%. Minerva Neurosciences has a consensus price target of $10.50, suggesting a potential upside of 124.84%. Given Instil Bio's higher possible upside, research analysts plainly believe Instil Bio is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Minerva Neurosciences' return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Minerva Neurosciences	N/A	N/A	-32.63%

Instil Bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Summary

Instil Bio beats Minerva Neurosciences on 8 of the 12 factors compared between the two stocks.

How does Instil Bio compare to Inhibikase Therapeutics?

Instil Bio (NASDAQ:TIL) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.89 beat Inhibikase Therapeutics' score of 0.59 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Inhibikase Therapeutics	Positive

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 727.07%. Inhibikase Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 225.30%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Instil Bio's return on equity of -39.76% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Instil Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Inhibikase Therapeutics has higher revenue and earnings than Instil Bio. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Inhibikase Therapeutics	$260K	842.96	-$48.26M	-$0.43	N/A

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Instil Bio beats Inhibikase Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TIL vs. The Competition

Export

Metric	Instil Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$54.10M	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-1.13	18.99	24.49	23.62
Price / Sales	N/A	290.48	500.49	105.27
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	0.48	8.00	10.43	6.70
Net Income	-$71.37M	$23.89M	$3.56B	$337.26M
7 Day Performance	-3.04%	-3.49%	-1.38%	-1.41%
1 Month Performance	-2.21%	1.02%	0.86%	1.15%
1 Year Performance	-78.75%	34.39%	19.43%	22.61%

Instil Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TIL Instil Bio	2.0167 of 5 stars	$7.98 -0.5%	$66.00 +727.1%	-77.1%	$54.10M	N/A	N/A	410	Positive News
CHRS Coherus Oncology	3.663 of 5 stars	$1.42 flat	$8.67 +510.3%	+66.2%	$219.04M	$42.17M	0.85	330	Positive News
FHTX Foghorn Therapeutics	2.9684 of 5 stars	$3.87 +4.3%	$11.43 +195.3%	-15.7%	$217.83M	$30.91M	N/A	120	News Coverage
FBRX Forte Biosciences	1.8978 of 5 stars	$17.00 +8.5%	$67.00 +294.1%	+42.3%	$217.59M	N/A	N/A	5	News Coverage
NERV Minerva Neurosciences	3.1438 of 5 stars	$4.74 +2.4%	$10.50 +121.5%	+157.6%	$215.71M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TIL) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Instil Bio (TIL) Competitors

TIL vs. CHRS, FHTX, FBRX, NERV, and IKT

How does Instil Bio compare to Coherus Oncology?

Summary

How does Instil Bio compare to Foghorn Therapeutics?

Summary

How does Instil Bio compare to Forte Biosciences?

Summary

How does Instil Bio compare to Minerva Neurosciences?

Summary

How does Instil Bio compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Instil Bio (TIL) Competitors

TIL vs. CHRS, FHTX, FBRX, NERV, and IKT

How does Instil Bio compare to Coherus Oncology?

Do analysts rate TIL or CHRS?

Does the media refer more to TIL or CHRS?

Which has more risk & volatility, TIL or CHRS?

Do insiders and institutionals hold more shares of TIL or CHRS?

Which has better earnings & valuation, TIL or CHRS?

Is TIL or CHRS more profitable?

Summary

How does Instil Bio compare to Foghorn Therapeutics?

Is TIL or FHTX more profitable?

Do analysts recommend TIL or FHTX?

Does the media refer more to TIL or FHTX?

Which has preferable earnings and valuation, TIL or FHTX?

Do insiders & institutionals have more ownership in TIL or FHTX?

Which has more risk & volatility, TIL or FHTX?

Summary

How does Instil Bio compare to Forte Biosciences?

Do insiders and institutionals believe in TIL or FBRX?

Do analysts rate TIL or FBRX?

Is TIL or FBRX more profitable?

Which has preferable valuation and earnings, TIL or FBRX?

Does the media favor TIL or FBRX?

Which has more risk & volatility, TIL or FBRX?

Summary

How does Instil Bio compare to Minerva Neurosciences?

Does the media prefer TIL or NERV?

Which has more risk & volatility, TIL or NERV?

Do institutionals and insiders hold more shares of TIL or NERV?

Do analysts prefer TIL or NERV?

Is TIL or NERV more profitable?

Which has better valuation & earnings, TIL or NERV?

Summary

How does Instil Bio compare to Inhibikase Therapeutics?

Does the media favor TIL or IKT?

Do analysts rate TIL or IKT?

Is TIL or IKT more profitable?

Which has more risk & volatility, TIL or IKT?

Which has better earnings & valuation, TIL or IKT?

Do institutionals and insiders believe in TIL or IKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools